• 1
    Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917923.
  • 2
    Hu FB, Li TY, Colditz GA, Willett WC., Manson JE. Television watching and other sedentary behaviours in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003; 289: 17851791.
  • 3
    Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393403.
  • 4
    Jones NL, Killian KJ. Exercise limitation in health and disease. N Engl J Med 2000; 343: 632641.
  • 5
    Vamecq J, Latruffe N. Medical significance of peroxisome proliferatoractivated receptors. Lancet 1999; 354: 141148.
  • 6
    Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MJ. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280288.
  • 7
    Neuschwander-Tetri BA, Isley WL, Oki JC., Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM. Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 1998; 129: 3841.
  • 8
    Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC., Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519525.
    Direct Link:
  • 9
    Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller C., Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003; 38: 434440.
  • 10
    Brunt EM, Janney CJ, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999; 94: 24672474.
    Direct Link:
  • 11
    Luyckx FH, Desaive C., Thiry A, Dewé W, Scheen AJ, Gielen JE, Lefébvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222226.
  • 12
    Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 316.
  • 13
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC., McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 14131419.
  • 14
    Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002; 87: 144147.
  • 15
    Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 24022410.
  • 16
    Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J, Tajima N. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy—a randomized controlled trial. Metab Clin Exp 2001; 50: 414417.
  • 17
    Sanyal AJ, Contos MJ, Sargeant C., Stravitz RT, Luketic VA, Sterling RK, Shiffman ML. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for non-alcoholic steatohepatitis [Abstract]. Hepatology 2002; 36: A382.
  • 18
    Azuma T, Tomita K, Kato S, Adachi M, Inokuchi N, Kitamura N, Nishimura T, et al. A pilot study of a thiazolidinediones, pioglitazone, in nonalcoholic steatohepatitis [Abstract]. Hepatology 2002; 36: 406A.
  • 19
    Phillips LS, Grunberger G, Miller E, Parwardhan R, Rappaport EB, Salzman A, for the Rosiglitazone Clinical Trials Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308315.
  • 20
    Ricote M, Li AC., Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 7982.
  • 21
    Jiang C., Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 8286.
  • 22
    Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart J-C., et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 2557325580.
  • 23
    Boelsterli UA, Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem Pharmacol 2002; 63: 110.
  • 24
    Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF, Motomura K, Anania F, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 46: 3571535722.
  • 25
    Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 19241940.